Calithera Biosciences Performance
| CALADelisted Stock | USD 0.05 0.00 0.00% |
The firm shows a Beta (market volatility) of -3.71, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Calithera Biosciences are expected to decrease by larger amounts. On the other hand, during market turmoil, Calithera Biosciences is expected to outperform it. Calithera Biosciences right now shows a risk of 0.0%. Please confirm Calithera Biosciences information ratio, treynor ratio, downside variance, as well as the relationship between the total risk alpha and value at risk , to decide if Calithera Biosciences will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Calithera Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong essential indicators, Calithera Biosciences is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 59.8 M |
Calithera |
Calithera Biosciences Relative Risk vs. Return Landscape
If you would invest 5.00 in Calithera Biosciences on September 1, 2024 and sell it today you would earn a total of 0.00 from holding Calithera Biosciences or generate 0.0% return on investment over 90 days. Calithera Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Calithera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Calithera Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Calithera Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Calithera Biosciences, and traders can use it to determine the average amount a Calithera Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CALA |
Based on monthly moving average Calithera Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Calithera Biosciences by adding Calithera Biosciences to a well-diversified portfolio.
Calithera Biosciences Fundamentals Growth
Calithera Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Calithera Biosciences, and Calithera Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Calithera Pink Sheet performance.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | (1.1 M) | ||||
| Shares Outstanding | 4.87 M | ||||
| Price To Earning | (14.08) X | ||||
| Price To Book | 1.86 X | ||||
| Price To Sales | 1.71 X | ||||
| EBITDA | (43.77 M) | ||||
| Cash And Equivalents | 41.79 M | ||||
| Cash Per Share | 8.59 X | ||||
| Total Debt | 1.67 M | ||||
| Debt To Equity | 0.07 % | ||||
| Book Value Per Share | (0.40) X | ||||
| Cash Flow From Operations | (43.61 M) | ||||
| Earnings Per Share | (1.59) X | ||||
| Total Asset | 28.68 M | ||||
| Retained Earnings | (512.62 M) | ||||
| Current Asset | 72.5 M | ||||
| Current Liabilities | 3.83 M | ||||
About Calithera Biosciences Performance
By analyzing Calithera Biosciences' fundamental ratios, stakeholders can gain valuable insights into Calithera Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Calithera Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Calithera Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California. Calithera Biosci operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 63 people.Things to note about Calithera Biosciences performance evaluation
Checking the ongoing alerts about Calithera Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Calithera Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Calithera Biosciences is not yet fully synchronised with the market data | |
| Calithera Biosciences has some characteristics of a very speculative penny stock | |
| Calithera Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (39.65 M) with loss before overhead, payroll, taxes, and interest of (42.7 M). | |
| Calithera Biosciences currently holds about 41.79 M in cash with (43.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Calithera Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Calithera Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Calithera Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Calithera Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Calithera Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Calithera Biosciences' pink sheet. These opinions can provide insight into Calithera Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Calithera Pink Sheet
If you are still planning to invest in Calithera Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calithera Biosciences' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |